stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) EV/FCF
As of 5 November 2026, Vericel Corporation (VCEL) trades at a EV/FCF of 42.8×. Over the past ten years it has ranged from −1,140× (August 2024) to 1,201× (April 2024); the current reading is higher than 62% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 68.4× | — |
| FY2024 | −443× | — |
| FY2023 | 199× | 85.34% |
| FY2022 | 107× | 30.18% |
| FY2021 | 82.4× | (7.97%) |
| FY2020 | 89.5× | — |
| FY2019 | −73.1× | — |
| FY2018 | −205× | — |
| FY2017 | −12.7× | — |
| FY2016 | −2.5× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 32.8× | (4.78%) |
| Jun 2026 | 34.5× | 8.82% |
| Mar 2026 | 31.7× | (53.65%) |
| Dec 2025 | 68.4× | (5.25%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | −62.4× |
| PHVS Pharvaris N.V. compare | −10.5× |
| IMNM Immunome, Inc. compare | −7.0× |
| CLDX Celldex Therapeutics, Inc. compare | −6.2× |
| VERA Vera Therapeutics, Inc. compare | −5.2× |
| BHVN Biohaven Ltd. compare | −4.5× |
| AUPH Aurinia Pharmaceuticals Inc compare | 9.7× |
| ADMA ADMA Biologics Inc compare | 25.2× |
| VCEL Vericel Corporation | 42.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement